Compare SOLAI Limited (SLAI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

SOLAI LimitedTrade

State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

SOLAI Limited vs State Street SPDR S&P Biotech ETF — how do they compare? SOLAI Limited trades at $3.72 (market cap $16.69M), while State Street SPDR S&P Biotech ETF trades at $154.49. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.

	SLAI	XBI
Market Cap	$16.69M	—
Sector	Technology	Broad Market / Factor
52-Week High	$26.74	$164.28
52-Week Low	$2.74	$85.16
Enterprise Value	$16.33M	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

SLAI

SOLAI Limited to be delisted from NYSE due to low market cap, plans OTC market listing.PRNewsWire · 14 hours agoBearish View details →

XBI

Healthcare ETFs lead State Street's top 5 performers with pharma fund gaining 11.7% in the past monthETF Trends · 4 days agoBullish View details →

About SOLAI Limited

SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.